Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1251

Sort by

Sort Order Select

Journal Articles

Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET + PR appropriate in the CAR T-cell era? Blood . 2021;137(10):1416-1423.

Blood (2021) 137 (20): 2854–2855.

https://doi.org/10.1182/blood.2021011979

Published: 2021

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Is autologous transplant in relapsed DLBCL patients achieving only a PET + PR appropriate in the CAR T-cell era?

Nirav N. Shah, Kwang W. Ahn, Carlos Litovich, Yizeng He, Craig Sauter, Timothy S. Fenske, Mehdi Hamadani

Blood (2021) 137 (10): 1416–1423.

https://doi.org/10.1182/blood.2020007939

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett

Blood (2020) 135 (25): 2224–2234.

https://doi.org/10.1182/blood.2019003277

Published: 2020

Includes: Supplemental data

Journal Articles

ΔSUVmax for interim PET in DLBCL: old is new

Michel Meignan, Andrea Gallamini

Blood (2020) 135 (25): 2202–2203.

https://doi.org/10.1182/blood.2020005649

Published: 2020

Journal Articles

Predicting the future for DLBCL

Bruce D. Cheson

Blood (2020) 135 (16): 1308–1309.

https://doi.org/10.1182/blood.2020005002

Published: 2020

Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Blood (2020) 135 (16): 1396–1405.

https://doi.org/10.1182/blood.2019003526

Published: 2020

Includes: Supplemental data

Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman

Blood (2020) 135 (15): 1214–1218.

https://doi.org/10.1182/blood.2019001091

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Core Biopsies Performed By Experienced Radiologists and Analysed By Expert Haemato-Pathologists Reliably Permit the Rapid and Safe Diagnosis of Lymphoproliferative Diseases and Negate the Need for Excisional Biopsy in Almost All Patients. Experience from 554 Sequential Core Biopsies from a Single Centre

Oliver C Cohen, MBBS, BSc, FRCPath, Max Brodermann, Aoife Dervin, MBBS, BSc, MRCP, Simon Morley, Ian Proctor, Neel Raja, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, William Townsend, MD FRCPath

Blood (2019) 134 (Supplement_1): 4746.

https://doi.org/10.1182/blood-2019-123698

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD

Blood (2019) 134 (Supplement_1): 883.

https://doi.org/10.1182/blood-2019-123450

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD

Blood (2019) 134 (Supplement_1): 884.

https://doi.org/10.1182/blood-2019-132057

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 1582.

https://doi.org/10.1182/blood-2019-122573

Published: 2019

Journal Articles

North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1553.

https://doi.org/10.1182/blood-2019-131276

Published: 2019

Journal Articles

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Heiko Schoder, MD, Jisun Lee, Theresa Davey, MMSc, PA-C, Helen Hancock, ANP, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, M. Lia Palomba, MD, Gunjan L. Shah, MDMS, Miguel-Angel Perales, MD, Craig S. Sauter, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 1555.

https://doi.org/10.1182/blood-2019-129364

Published: 2019

Journal Articles

Using Childhood International Prognostic Scoring in Pediatric Hodgkin Lymphoma Patients Treated with ABVD Can Mitigate Use of Interim PET in LMIC

Reham Khedr, MD, Hanaa Rashad, MD, Asmaa Mohammed Hamoda, MD PhD MSc, Eman Khorshed, PhD, Madeha Elwakeel, PhD, Mohamed Saad, MD, Engy Mohamed, Emad Moussa

Blood (2019) 134 (Supplement_1): 1562.

https://doi.org/10.1182/blood-2019-132195

Published: 2019

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

https://doi.org/10.1182/blood-2019-125256

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET + PR appropriate in the CAR T-cell era? Blood . 2021;137(10):1416-1423.

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Is autologous transplant in relapsed DLBCL patients achieving only a PET + PR appropriate in the CAR T-cell era?

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

ΔSUVmax for interim PET in DLBCL: old is new

Predicting the future for DLBCL

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Using Childhood International Prognostic Scoring in Pediatric Hodgkin Lymphoma Patients Treated with ABVD Can Mitigate Use of Interim PET in LMIC

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only